UMEZAWA et al. found that forphenicine, isolated from culture filtrates of Actinomycetes fulvoviridis var. acarbodicus is a specific inhibitor against chicken intestine alkaline phosphatase and it was shown to enhance delayed type hypersensitivity and antibody formation in mice1,2). Thereafter, ISHIZUKA et al. found that forphenicinol, a synthetic derivative of forphenicine, enhanced delayed type hypersensitivity and caused macrophage activation by oral administration3). Forphenicinol was also shown to exert an antitumor action and to exhibit a protective effect against an experimental Pseudomonas infection by mortality study'). The present work was designed to study the precise action of forphenicinol against Pseudomonas septicaemia in mice.
Female, specific pathogen free ICR mice were obtained from Shizuoka Laboratory Animal Agriculture Cooperative Association, Shizuoka, Japan. Seven-to ten-week old mice were used throughout the experiments.
Forphenicinol was kindly provided by Dr. H. UMEZAWA and Dr. S. OKA, Institute of Microbial Chemistry, Tokyo, Japan. It was prepared by Banyu Pharmaceutical Co., Ltd., Japan. It was dissolved in sterile saline and was administered orally in a volume of 0.1 ml.
Pseudomonas aeruginosa (strain NC-5) was provided originally by Dr. J. Y. HOMMA (Institute of Medical Science, Tokyo University, Japan). This strain was highly virulent for mice and produced neither exotoxin, protease nor lecithinase. Bacterial suspensions were made as described previously5). Mice were infected iv with the dose slightly higher than the LD50 in a volume of 0.1 ml. Challenged mice were observed for 7 days following infection. Bacterial enumeration in the kidneys was performed as described previously5). The viable counts were expressed in log10 units.
Bactericidal assay of peripheral blood was carried out as described previously6). Briefly, a mixture of 0.5 ml of heparinized blood and 0.2 ml of the Pseudomonas suspension was rotated 150 rpm on a Gyrotory at 37°C for 3 hours. Three hours after incubation, 0.1 ml of the mixture was serially diluted with distilled water and plated on nutrient agar.
Bacterial count was carried out after incubation at 37°C for 24 hours.
Nitroblue-tetrazolium (NBT) reduction in casein-induced peritoneal cells was performed Normal controls and forphenicinol-treated mice which had received the doses indicated of forphenicinol daily for 5 days were infected iv with 5.8 x 107 P. aeruginosa.
Each group consisted of 10 mice. Each group consisted of 10 mice. All mice were concurrently infected iv with 5.8 x 107 P. aeruginosa 1 hour after the last administration of forphenicinol.
As can be seen in Fig. 1 , forphenicinol-treated mice showed a lower rate of mortality as compared to controls. The difference between the mice receiving 10,ug of forphenicinol for 5 days and controls was significant to P<0.01. The next experiment was performed to examine the optimal timing of forphenicinol administration for protection against infection. A single dose of 50 ug forphenicinol was given 1 hour, 1, 2 and 3 days before infection respectively. Mice were infected iv with 2.9 x 107 P. aeruginosa. As shown in Fig. 2 , the survival rate was higher in mice receiving forphenicinol within 2 days before infection as compared to controls. However, there was no significant difference between control and experimental groups. In the next experiment, the experimental group of mice was given 10 pg of forphenicinol daily for 3 days. Mice were infected iv with 4.4 x 107 P. aeruginosa 1 day after the last administration of forphenicinol. Survival was 70% in forphenicinol-treated mice and 60% in controls.
The results of bacterial counts in the kidneys of survivors are presented in Table 1 . The numbers of bacteria in forphenicinol-treated mice were almost ten times lower than those in controls, although the difference was not statistically significant.
The in vitro bactericidal activity of peripheral blood obtained from forphenicinol-treated mice was compared with that of normal controls. The results in Table 2 showed that the number of bacteria in the blood from forphenicinol-treated mice was apparently lower than that of controls.
NBT reduction in casein-induced peritoneal neutrophils was examined. As shown in Table 3 , Normal controls and forphenicinol-treated mice which had received 10 pg of forphenicinol daily for 3 days were infected iv with 4.4 x 107 P. aeruginosa.
Bacterial counts were performed in the kidneys of survivors 7 days after infection. Mean of log10 viable Pseudomonas/ 0.1 ml recovered after 3 hours of incubation 5.62±0.21 4.96+0.22* Normal controls and forphenicinol-treated mice which had received 10 pg of forphenicinol daily for 5 days were sacrificed 1 hour after the last administration of forphenicinol.
Peripheral blood was obtained by heart puncture. Mean number of Pseudomonas at zero time was 4.5 x 105 cells/0.1 ml of sample (expressed in log10, 5.65). * P<0 .005 in comparison with control. Normal controls and forphenicinol-treated mice which had received 20 pg of forphenicinol daily for 3 days were injected ip with 0.2 ml of 5 % sodium caseinate in saline 1 hour after the last administration of forphenicinol.
At the various times indicated after casein injection, peritoneal cells were obtained by washing out the peritoneal cavity with HANK'S balanced salt solution containing 5 u/ml of heparin.
Each value represents the mean of five mice. * P<0 .01 in comparison with control. 
